6 replies to this topic

[tham]

The two newer independent predictors for heart attacks
and strokes are lipoprotein (a) - ( Lp(a) ), and
lipoprotein-phospholipase A2 - (Lp-PLA2).

http://www.naturalch...eartDisease.htm

http://www.c-reactiv...ein.com/103.htm

http://www.lef.org/L...px?CmsID=113832


Lp(a) can be lowered with niacin or the niacin-bound form of
vitamin E known as tocopherol nicotinate, manufactured in
Japan by Eisai as "Hijuven" and the German drug firm Mack
in Europe as "Renascin".

http://www.ncbi.nlm....l=pubmed_docsum


Does anyone know which supplement might reduce Lp-PLA2 ?

[Pablo M]

Tham, I am sure you are familiar with the Pauling therapy for lowering Lp(a). It consists of lysine, proline and vitamin C. Matthias Rath and Owen Fonorow go so far as to call it a "cure" for heart disease. I think this is a bit of an exaggeration, but it looks promising.

Many of the therapies listed above for the treatment of elevations of CRP are thought likely to also help with elevations of Lp-PLA2.

(from here) So I guess anti-inflammatories are in order. [downs 1/4 tsp of vitamin C powder]

[tham]

Thanks, Pablo.

I was under the impression that Pauling's and Matthias Rath's
advocacy of C, lysine and proline only strengthened collagen
and thus improved the viability of the atheroscelerotic arteries.
Apparently Tom Matthews, the former moderator of LEF, found
this work of Rath somewhat controversial.

http://forum.lef.org...m=16972&g=21357


Yes, you were correct. Niacin lowers blood Lp-PLA2 levels. But,
like the statins, (and one study found only atorvastatin to have
any real effect in lowering it in blood) it does not appear likely to
lower its upregulation by macrophages in atheroscelerotic plaque.

http://www.prnewswir...04319559&EDATE=


"Although various lipid-lowering therapies, such as statins, have been shown to reduce plasma levels of Lp-PLA2, none has been studied in terms of its ability to lower the large macrophage-mediated upregulation of Lp-PLA2 within advanced plaques."

http://www.ncbi.nlm....l=pubmed_docsum


Glaxo, which partly owns DiaDexus, the company marketing the
PLAC test for Lp-PLA2, is developing a drug to inhibit it, but I
would expect it to have significant side effects like the statins.

http://www.ncbi.nlm....earch&DB=pubmed

http://www.businessw..._4514_db090.htm



http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum


http://www.apollolip...d=4473&zoneid=1

http://www.medicalne...hp?newsid=41449



Lp(a) :

Regarding tocopherol nicotinate, "Hijuven" is its brand name marketed by Eisai in Malaysia and Thailand. The brand name
in Japan is "Juvela-N".

I downloaded this PDF file some years ago, but can't find the
link anymore, so I scanned it.

http://www.geocities...ibose_heart/Lpa


Note that both Lp(a) and Lp-PLA2 are predictors independent
of ApoA1/ApoB ratios, homocysteine and hs-CRP.

Edited by tham, 29 July 2006 - 03:45 PM.

[Pablo M]

I wonder why this study abstract is not available on PubMed? [referring to Rath-Pauling protocol]

Well for one, the Journal of Orthomolecular Medicine is not provided on MedLine, in what some have called a case of censorship.

[tham]

Sorry, this was the correct Medline link above for the Glaxo drug in
development to inhibit Lp-PLA2.

http://www.ncbi.nlm....t_uids=12643913

[tham]

Managed to find these two Korean studies.

Erigeron annuus is the daisy fleabane, considered a weed
in south-eastern USA.

http://www.ncbi.nlm....l=pubmed_docsum


Saururus chinensis is used in Chinese and Japanese
herbal medicine. Common names Chinese Lizard'sTail or
Golden Lizard's Tail. I think one could probably buy it
at Chinese herbal stores.

http://www.ncbi.nlm....l=pubmed_docsum


It's even used in this detoxifying footpatch.

http://takara.jeffot...s_chinensis.htm


Almost all the studies on Medline are Korean, with its
lignans and flavonoids showing potent antioxidant,
antiinflammatory, neuroprotective and anticancer properties.

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum

[tham]

Found and downloaded this extensive Korean study a few days
ago, but apparently the link seems difficult to access again.
Perhaps they have blocked it.

http://lipid.kribb.r...n/paper_in2.pdf


I've uploaded the PDF file here. The study is in Korean,
but the abstract and plant botanical names are English.
Note that the Glaxo drug being developed, SB-480848,
is mentioned at the end of the study.

http://geocities.com...PLA2/PLANTS.pdf


Several of these plants show inhibition of Lp-PLA2
up to 60 %, however these are not really easily
commercially accessible or edible, the parts used
being stems, roots, etc ., and some were big trees
in Japan and Korea.


Three others are easily available :

1. Pyrus ussuriensis - which is apparently the common
yellow Chinese or sand pear, inhibits 52%. The part tested
was the leaf, but the fruit likely bears a good proportion
of the active lignans and flavonoids. I believe this pear can
be found everywhere in supermarkets in the USA.

http://www.ars-grin....ssuriensis1.jpg


2. Schizandra chinensis - inhibits a respectable 38 %.
The reddish berries which look a bit like raisins are
commonly used as an adaptogen in Chinese and Western herbal medicine, and also has heart, liver and cancer supportive
properties. Its common name translated from Chinese literarily means "Five Tastes Fruit".

The parts studied were the leaf and flower, so the fruit
should also have a good deal of the active fractions.
Can be found as whole herb or extract from most health
food stores. The dried berry can be found in any Chinese
herbal store, though you would have to boil them. Supposed
to be contraindicated in gastritis, epilepsy and hypertension.

http://www.bodyandfi.../schizandra.htm

http://betterlife.co...sp?prod_id=5735

http://betterlife.co...sp?prod_id=2402


http://www.ncbi.nlm....l=pubmed_docsum

http://www.ncbi.nlm....l=pubmed_docsum


3. Thea sinensis - inhibits a significant 36 % (leaves), and is
supposed to be synonymous with camellia sinensis - green
and black teas.

Edited by tham, 14 January 2007 - 03:56 PM.